JOHNSON & JOHNSON 853260 - wohl das am konstantesten wachsende Unternehmen der Welt (Seite 52)
eröffnet am 22.11.07 16:46:06 von
neuester Beitrag 16.04.24 18:01:52 von
neuester Beitrag 16.04.24 18:01:52 von
Beiträge: 601
ID: 1.135.563
ID: 1.135.563
Aufrufe heute: 464
Gesamt: 129.372
Gesamt: 129.372
Aktive User: 1
ISIN: US4781601046 · WKN: 853260 · Symbol: JNJ
144,56
USD
-2,05 %
-3,03 USD
Letzter Kurs 19:48:08 NYSE
Neuigkeiten
15:58 Uhr · wallstreetONLINE Redaktion |
| Johnson & Johnson Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!Anzeige |
17:50 Uhr · wO Newsflash |
16:33 Uhr · dpa-AFX |
Earnings Season: Dividendenerhöhung Nummer 62 – Johnson & Johnson mit Zahlen!Werte aus der Branche Konsum
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,2600 | +135,34 | |
| 1,9000 | +100,00 | |
| 21,870 | +10,01 | |
| 2,2500 | +9,22 | |
| 7,2900 | +8,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,7500 | -10,04 | |
| 12,750 | -10,21 | |
| 1,8000 | -10,22 | |
| 15,710 | -13,54 | |
| 1,4000 | -35,93 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 35.994.293 von spaceistheplace am 18.11.08 18:55:21Guten Morgen,
ja die Vola ist sehr groß und der Dow fiel gestern unter die berüchtigte 8000er Marke. Nach Ansicht der Charttechniker darf er sich dort nicht sehr lange aufhalten, sonst besteht die Gefahr dass er durchrasselt u.U. bis auf erschreckende 4000!!
Der Wert eines Unternehmens ist sehr wichtig, spielt jedoch mMn in panischen Momenten keine Rolle, der Kurs wird einfach mitgerissen.
Wollen wir hoffen dass der Dow wieder über die bewusste Marke geht und dieser "Worst Case" nicht eintritt!
Gruß,
Shaba
ja die Vola ist sehr groß und der Dow fiel gestern unter die berüchtigte 8000er Marke. Nach Ansicht der Charttechniker darf er sich dort nicht sehr lange aufhalten, sonst besteht die Gefahr dass er durchrasselt u.U. bis auf erschreckende 4000!!
Der Wert eines Unternehmens ist sehr wichtig, spielt jedoch mMn in panischen Momenten keine Rolle, der Kurs wird einfach mitgerissen.
Wollen wir hoffen dass der Dow wieder über die bewusste Marke geht und dieser "Worst Case" nicht eintritt!
Gruß,
Shaba
Antwort auf Beitrag Nr.: 35.993.304 von shaba am 18.11.08 17:44:08naja, ganz so schlecht ist der kurs ja doch nicht, im Moment wieder über 60$ und wenn der DOW weiter steigt oder zumindest diese +1,5% halten kann wirds wohl noch weitergehen.
bei dieser Volatilität aktuell, auch im DOW ist es heiteres beruferaten zu prognostizieren, wo der Dow schließen wird. ist gerade jeden tag so.
daher schaue ich gar nicht mehr groß hin, sollen sich alle austoben, ist mir egal.
Denn diese Kursschwankungen ändern am Unternehmen nichts.
Gut möglich, dass der DOW auch auf 7000 oder 6000 fallen kann, jedoch sollte das einen nicht beunruhigen.
nach dieser Krise werden wir jedenfalls gesündere Strukturen in der Finanzwelt haben...
Gruss space
bei dieser Volatilität aktuell, auch im DOW ist es heiteres beruferaten zu prognostizieren, wo der Dow schließen wird. ist gerade jeden tag so.
daher schaue ich gar nicht mehr groß hin, sollen sich alle austoben, ist mir egal.
Denn diese Kursschwankungen ändern am Unternehmen nichts.
Gut möglich, dass der DOW auch auf 7000 oder 6000 fallen kann, jedoch sollte das einen nicht beunruhigen.
nach dieser Krise werden wir jedenfalls gesündere Strukturen in der Finanzwelt haben...
Gruss space
Antwort auf Beitrag Nr.: 35.992.774 von spaceistheplace am 18.11.08 17:06:39naja, ganz so schlecht ist der kurs ja doch nicht, im Moment wieder über 60$ und wenn der DOW weiter steigt oder zumindest diese +1,5% halten kann wirds wohl noch weitergehen.
Gruß,
shaba
Gruß,
shaba
Antwort auf Beitrag Nr.: 35.992.606 von shaba am 18.11.08 16:54:53dem Kurs schadet oder bringts heute jedenfalls nicht viel. ich weiß auch nicht, wie stark solche meldungen auf die gewinnsituation dieses Großkonzernes wirken. Dürfte marginal sein...
Gruss space
Gruss space
Das freut uns aber wieder!
Magnetically Steered Irrigated Tip Cardiac Catheter for Treatment of Irregular Heart Rhythms Now Available Throughout the European Union
NAVISTAR® RMT THERMOCOOL® combines the safety of power-controlled irrigated tip technology with the control of remote magnetic navigation away from fluoroscopy exposure
Diamond Bar, CA (November 18, 2008) - Patients in the European Union (EU) with Atrial Fibrillation and other arrhythmias, also known as irregular heart rhythms, may now benefit from treatment with an innovative state-of-the art catheter. The NaviStar® RMT ThermoCool® Catheter is designed to maintain safe tip-to-tissue temperatures and gives physicians the safety and convenience of steering the catheter remotely away from fluoroscopy exposure during procedures to eliminate abnormal heart rhythms.
The NaviStar® RMT ThermoCool® Catheter for radiofrequency (RF) ablation is used with the NIOBE® Magnetic Navigation System, which helps steer a catheter remotely and guide ablation to targeted areas that require treatment.
The NaviStar® RMT ThermoCool® Catheter, manufactured by Biosense Webster, Inc., in combination with the Carto® RMT System can be used to create highly accurate 3D electroanatomical maps. Electrophysiologists are able to steer the NaviStar® RMT ThermoCool® Catheter using the integrated NIOBE® Navigation technology and a miniature location sensor is placed inside each catheter for real-time, high-resolution mapping.
“Remote magnetic navigation for Atrial Fibrillation ablation is feasible with a short learning curve,” said Carlo Pappone, MD, PhD, FACC, Director, Department of Arrhythmology, San Raffaele University Hospital, Milan, Italy. “Combined with the proven technology of open irrigation this is an essential tool, especially for complex ablations. As a physician, I am pleased that the product is now widely available.”
The British Standards Institution approved the NaviStar® RMT ThermoCool® Catheter for marketing in August 2008. Earlier this year Biosense Webster had withdrawn the catheter after an external evaluation of the product at nine sites within the EU and Canada. At that time, the company determined that the catheter was performing in a manner inconsistent with the product’s specifications. The inconsistencies have now been rectified, the external evaluation has been completed and the product is available throughout the EU.
RF ablation procedures are most often used to treat rapid, irregular heartbeats (cardiac arrhythmias). The procedure is performed by a doctor guiding the NaviStar® RMT ThermoCool® Catheter with the Niobe® Magnetic Navigation System to the area of heart muscle where cells are giving off electrical signals that stimulate the abnormal heart rhythm. An application of energy is then transmitted to those areas to carefully destroy those heart muscle cells that are conducting the extra impulses that caused the irregular heart rhythm.
“As leaders in electrophysiology, we take pride in transforming insightful ideas from the electrophysiology lab into enhanced technologies that improve procedures and make a difference for patients,” said Shlomi Nachman, Worldwide President, Biosense Webster, Inc. “We are pleased to officially launch this exciting product to electrophysiologists in the EU.”
Dr. Pappone is compensated for his services as a consultant to the Company.
About Biosense Webster, Inc.
Biosense Webster, Inc., a Johnson & Johnson company, pioneered EP diagnostic catheters more than 30 years ago and continues to lead the industry as an innovative provider of advanced diagnostic, therapeutic and mapping tools. As the leader in navigation systems, Biosense Webster, Inc.'s, technology includes the largest installed base of navigation systems worldwide in leading hospitals and teaching institutions. With proprietary products such as the CartoMerge™ Image Integration Software Module, the ThermoCool® Irrigated Tip Catheter and the Lasso® Circular Variable Mapping Catheter, the company is changing the way electrophysiologists diagnose and treat arrhythmias.
http://www.jnj.com/connect/news/all/20081118_080000
Magnetically Steered Irrigated Tip Cardiac Catheter for Treatment of Irregular Heart Rhythms Now Available Throughout the European Union
NAVISTAR® RMT THERMOCOOL® combines the safety of power-controlled irrigated tip technology with the control of remote magnetic navigation away from fluoroscopy exposure
Diamond Bar, CA (November 18, 2008) - Patients in the European Union (EU) with Atrial Fibrillation and other arrhythmias, also known as irregular heart rhythms, may now benefit from treatment with an innovative state-of-the art catheter. The NaviStar® RMT ThermoCool® Catheter is designed to maintain safe tip-to-tissue temperatures and gives physicians the safety and convenience of steering the catheter remotely away from fluoroscopy exposure during procedures to eliminate abnormal heart rhythms.
The NaviStar® RMT ThermoCool® Catheter for radiofrequency (RF) ablation is used with the NIOBE® Magnetic Navigation System, which helps steer a catheter remotely and guide ablation to targeted areas that require treatment.
The NaviStar® RMT ThermoCool® Catheter, manufactured by Biosense Webster, Inc., in combination with the Carto® RMT System can be used to create highly accurate 3D electroanatomical maps. Electrophysiologists are able to steer the NaviStar® RMT ThermoCool® Catheter using the integrated NIOBE® Navigation technology and a miniature location sensor is placed inside each catheter for real-time, high-resolution mapping.
“Remote magnetic navigation for Atrial Fibrillation ablation is feasible with a short learning curve,” said Carlo Pappone, MD, PhD, FACC, Director, Department of Arrhythmology, San Raffaele University Hospital, Milan, Italy. “Combined with the proven technology of open irrigation this is an essential tool, especially for complex ablations. As a physician, I am pleased that the product is now widely available.”
The British Standards Institution approved the NaviStar® RMT ThermoCool® Catheter for marketing in August 2008. Earlier this year Biosense Webster had withdrawn the catheter after an external evaluation of the product at nine sites within the EU and Canada. At that time, the company determined that the catheter was performing in a manner inconsistent with the product’s specifications. The inconsistencies have now been rectified, the external evaluation has been completed and the product is available throughout the EU.
RF ablation procedures are most often used to treat rapid, irregular heartbeats (cardiac arrhythmias). The procedure is performed by a doctor guiding the NaviStar® RMT ThermoCool® Catheter with the Niobe® Magnetic Navigation System to the area of heart muscle where cells are giving off electrical signals that stimulate the abnormal heart rhythm. An application of energy is then transmitted to those areas to carefully destroy those heart muscle cells that are conducting the extra impulses that caused the irregular heart rhythm.
“As leaders in electrophysiology, we take pride in transforming insightful ideas from the electrophysiology lab into enhanced technologies that improve procedures and make a difference for patients,” said Shlomi Nachman, Worldwide President, Biosense Webster, Inc. “We are pleased to officially launch this exciting product to electrophysiologists in the EU.”
Dr. Pappone is compensated for his services as a consultant to the Company.
About Biosense Webster, Inc.
Biosense Webster, Inc., a Johnson & Johnson company, pioneered EP diagnostic catheters more than 30 years ago and continues to lead the industry as an innovative provider of advanced diagnostic, therapeutic and mapping tools. As the leader in navigation systems, Biosense Webster, Inc.'s, technology includes the largest installed base of navigation systems worldwide in leading hospitals and teaching institutions. With proprietary products such as the CartoMerge™ Image Integration Software Module, the ThermoCool® Irrigated Tip Catheter and the Lasso® Circular Variable Mapping Catheter, the company is changing the way electrophysiologists diagnose and treat arrhythmias.
http://www.jnj.com/connect/news/all/20081118_080000
Trading Spotlight
Nicht sehr angenehm!
NEW YORK (Associated Press) - Two Johnson & Johnson subsidiaries that make and distribute a painkilling skin patch must pay nearly $16.6 million to the family of a suburban woman who died from a drug overdose while using the product, a jury ruled Monday.
Janice DiCosolo, 38, of Cicero died on Feb. 15, 2004, while using a Duragesic patch that her doctor prescribed to reduce pain caused by a neurological condition called reflex sympathetic dystrophy, her attorneys said.
The mother of three died because the patch delivered a fatal dose of its main ingredient, the powerful narcotic pain reliever fentanyl, jurors ruled Monday in Cook County Circuit Court following a three-week trial.
The defendants, Titusville, N.J.-based Janssen Pharmaceutica Inc. and Mountain View, Calif.-based ALZA Corp., knew about problems with the Duragesic patch that allowed it to leak fentanyl in doses large enough to kill patients, the lawsuit claimed. Both companies are subsidiaries of New Brunswick, N.J.-based Johnson & Johnson.
"They knew this patch was dangerous and defective but they continued to sell it and make money, and that's the only reason Janice DiCosolo is dead," Jim Orr, an attorney for DiCosolo's family, said in a statement.
Greg Panico, a spokesman for Janssen and ALZA, said Monday that the companies sympathize with DiCosolo's family but disagree with the jury's verdict.
The companies are considering options for an appeal, Panico said in a statement.
"This is a very unfortunate case for everyone, but we maintain that the patch was not defective," he said.
An independent expert and company expert inspected the patch that DiCosolo used and concluded there was no defect, Panico said. The companies believe DiCosolo's cause of death was polypharmacy, "a mix of multiple and potentially incompatible medications," he said.
Duragesic is a prescription-only product that is intended for cancer patients and others with chronic pain and is designed to dispense the medicine slowly through the skin.
The verdict is the fourth trial loss for the companies since 2006, DiCosolo's attorneys said.
A Sanford, Fla., jury last month awarded $13.3 million to the family of Susan Hodgemire, 34, who died after undergoing back surgery and using the Duragesic patch. In June 2007 a federal jury awarded $5.5 million to the father of a 28-year-old man who died in 2003 while wearing the patch.
The Food and Drug Administration issued two warnings in two years about improper use of fentanyl patches.
Some of the deaths came after doctors prescribed the patches to the wrong patients, the FDA said in December 2007. Patients could also accidentally overdose by using the patches wrong, the FDA said.
Some patches containing fentanyl were recalled in February 2008 because of a flaw that could cause them to leak. Those patches were sold in the United States by Actavis South Atlantic LLC and had both that name and the company's former name, Abrika Pharmaceuticals Inc., on the packaging.
Also in February, PriCara, another Johnson & Johnson division announced a recall of fentanyl patches manufactured by ALZA Corp.
The patches were first approved under the brand name Duragesic in 1990. A generic version hit the market in 2005.
http://money.cnn.com/news/newsfeeds/articles/apwire/37006f4b…
NEW YORK (Associated Press) - Two Johnson & Johnson subsidiaries that make and distribute a painkilling skin patch must pay nearly $16.6 million to the family of a suburban woman who died from a drug overdose while using the product, a jury ruled Monday.
Janice DiCosolo, 38, of Cicero died on Feb. 15, 2004, while using a Duragesic patch that her doctor prescribed to reduce pain caused by a neurological condition called reflex sympathetic dystrophy, her attorneys said.
The mother of three died because the patch delivered a fatal dose of its main ingredient, the powerful narcotic pain reliever fentanyl, jurors ruled Monday in Cook County Circuit Court following a three-week trial.
The defendants, Titusville, N.J.-based Janssen Pharmaceutica Inc. and Mountain View, Calif.-based ALZA Corp., knew about problems with the Duragesic patch that allowed it to leak fentanyl in doses large enough to kill patients, the lawsuit claimed. Both companies are subsidiaries of New Brunswick, N.J.-based Johnson & Johnson.
"They knew this patch was dangerous and defective but they continued to sell it and make money, and that's the only reason Janice DiCosolo is dead," Jim Orr, an attorney for DiCosolo's family, said in a statement.
Greg Panico, a spokesman for Janssen and ALZA, said Monday that the companies sympathize with DiCosolo's family but disagree with the jury's verdict.
The companies are considering options for an appeal, Panico said in a statement.
"This is a very unfortunate case for everyone, but we maintain that the patch was not defective," he said.
An independent expert and company expert inspected the patch that DiCosolo used and concluded there was no defect, Panico said. The companies believe DiCosolo's cause of death was polypharmacy, "a mix of multiple and potentially incompatible medications," he said.
Duragesic is a prescription-only product that is intended for cancer patients and others with chronic pain and is designed to dispense the medicine slowly through the skin.
The verdict is the fourth trial loss for the companies since 2006, DiCosolo's attorneys said.
A Sanford, Fla., jury last month awarded $13.3 million to the family of Susan Hodgemire, 34, who died after undergoing back surgery and using the Duragesic patch. In June 2007 a federal jury awarded $5.5 million to the father of a 28-year-old man who died in 2003 while wearing the patch.
The Food and Drug Administration issued two warnings in two years about improper use of fentanyl patches.
Some of the deaths came after doctors prescribed the patches to the wrong patients, the FDA said in December 2007. Patients could also accidentally overdose by using the patches wrong, the FDA said.
Some patches containing fentanyl were recalled in February 2008 because of a flaw that could cause them to leak. Those patches were sold in the United States by Actavis South Atlantic LLC and had both that name and the company's former name, Abrika Pharmaceuticals Inc., on the packaging.
Also in February, PriCara, another Johnson & Johnson division announced a recall of fentanyl patches manufactured by ALZA Corp.
The patches were first approved under the brand name Duragesic in 1990. A generic version hit the market in 2005.
http://money.cnn.com/news/newsfeeds/articles/apwire/37006f4b…
Antwort auf Beitrag Nr.: 35.949.953 von spaceistheplace am 14.11.08 18:24:12Ich sehe schon; ich weiss noch viel zuwenig über JNJ
nochmals, schönes w.ende!
shaba
nochmals, schönes w.ende!
shaba
Antwort auf Beitrag Nr.: 35.947.790 von shaba am 14.11.08 15:05:14und die windeln werden auch regelmässig "gefüllt"
Windeln hat JNJ nicht. Wenn Du Pampers meinst, dann sind die von PG. Auch das eines der besten Unternehmen weltweit
Aber egal....
Gruss und schönes WoEnde
Windeln hat JNJ nicht. Wenn Du Pampers meinst, dann sind die von PG. Auch das eines der besten Unternehmen weltweit
Aber egal....
Gruss und schönes WoEnde
Antwort auf Beitrag Nr.: 35.947.703 von spaceistheplace am 14.11.08 14:55:54(bebe, fenjal, tampons etc.)
und die windeln werden auch regelmässig "gefüllt"
das mit den aktiensplits ist natürlich um vieles besser, werde mich darauf einstellen!
ebenfalls ein angenehmes wochenende!
gruss,
shaba
und die windeln werden auch regelmässig "gefüllt"
das mit den aktiensplits ist natürlich um vieles besser, werde mich darauf einstellen!
ebenfalls ein angenehmes wochenende!
gruss,
shaba
Antwort auf Beitrag Nr.: 35.947.653 von shaba am 14.11.08 14:49:45giganten der pharmabranche
Pharma macht rd. 1/3 aus, Medtech noch mal so viel und consumer staples (bebe, fenjal, tampons etc.) noch mal ein Drittel, also breit aufgestellt. gerade die Pharmabranche wächst aktuell nicht.
ich gehe davon aus dass du bereits längere zeit bei JNJ investiert bist und dadurch auch am letzten stand.
jou, mit Unterbrechungen seit 1995
wie siehst du das target innerhalb der nächsten 12 monate? ist 70$ realistisch?
habe ich nicht, bin Langfristinvestor und da habe ich keine Kursziele. Langfristig zählen nur die Aktiensplits...
ich werde gerne mitarbeiten und mir alles zugängliche und auch interessante hier einstellen.
jou, nur zu! Dann muss ich es hier nicht alleine machen wie bisher.
Gruss und schönes Wochenende
space
Pharma macht rd. 1/3 aus, Medtech noch mal so viel und consumer staples (bebe, fenjal, tampons etc.) noch mal ein Drittel, also breit aufgestellt. gerade die Pharmabranche wächst aktuell nicht.
ich gehe davon aus dass du bereits längere zeit bei JNJ investiert bist und dadurch auch am letzten stand.
jou, mit Unterbrechungen seit 1995
wie siehst du das target innerhalb der nächsten 12 monate? ist 70$ realistisch?
habe ich nicht, bin Langfristinvestor und da habe ich keine Kursziele. Langfristig zählen nur die Aktiensplits...
ich werde gerne mitarbeiten und mir alles zugängliche und auch interessante hier einstellen.
jou, nur zu! Dann muss ich es hier nicht alleine machen wie bisher.
Gruss und schönes Wochenende
space
Durchsuchen
17:50 Uhr · wO Newsflash · Honeywell International |
16:33 Uhr · dpa-AFX · Morgan Stanley |
16:14 Uhr · Der Aktionär TV · Barrick Gold Corporation  |
15:58 Uhr · wallstreetONLINE Redaktion · Johnson & Johnson |
15:20 Uhr · dpa-AFX · Beiersdorf |
14:56 Uhr · dpa-AFX · CVS Health |
13:39 Uhr · dpa-AFX · Johnson & Johnson |
12:25 Uhr · Business Wire (engl.) · Johnson & Johnson  |
12:20 Uhr · Business Wire (engl.) · Johnson & Johnson |
04:30 Uhr · wallstreetONLINE Redaktion · Beiersdorf |